CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition

Two out of 41 non-small cell lung cancer patients enrolled in a clinical study were found with a somatic CRAF mutation in their tumor, namely CRAF(P261A) and CRAF(P207S). To our knowledge, both mutations are novel in lung cancer and CRAF(P261A) has not been previously reported in cancer. Expression...

Descripción completa

Detalles Bibliográficos
Autores principales: Noeparast, Amir, Giron, Philippe, Noor, Alfiah, Bahadur Shahi, Rajendra, De Brakeleer, Sylvia, Eggermont, Carolien, Vandenplas, Hugo, Boeckx, Bram, Lambrechts, Diether, De Grève, Jacques, Teugels, Erik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756226/
https://www.ncbi.nlm.nih.gov/pubmed/31285551
http://dx.doi.org/10.1038/s41388-019-0866-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756226/
https://www.ncbi.nlm.nih.gov/pubmed/31285551
http://dx.doi.org/10.1038/s41388-019-0866-7

Ejemplares similares